Quantcast

InteRNA Technologies Announces Establishment of Scientific Advisory Board

July 8, 2010

UTRECHT, the Netherlands, July 8, 2010 /PRNewswire/ — InteRNA
Technologies B.V., a biopharmaceutical company focusing on the development of
intelligent microRNA (miRNA)-based therapeutics for cancer, announces the
establishment of its Scientific Advisory Board (SAB). The SAB will further
guide the Company in the development of cancer therapies based on the unique
functions of its proprietary miRNAs.

The SAB is chaired by Emile E. Voest, MD, PhD, Professor of Medical
Oncology at the Department of Medical Oncology, UMC Utrecht, the Netherlands.

    Other distinguished members are:

    - Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department.
      of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center,
      Rotterdam, the Netherlands;

    - William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard
      Medical School, Dana-Farber Cancer Institute and Senior Associate
      Member at the Broad Institute of Harvard and MIT, Boston, USA;

    - Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in
      Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer
      Center, San Francisco, USA;

    - Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen,
      Belgium;

    - Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and
      Professor of Genome Biology at Utrecht University, Professor of Human
      Genetics and head of the Research section of the Department of Medical
      Genetics, UMC Utrecht and staff scientist at Hubrecht Institute,
      Utrecht, the Netherlands;

    - Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies
      and staff scientist at Hubrecht Institute, the Netherlands.

“We are very pleased with the formation of our SAB and feel honored to
collaborate with this experienced team that is highly committed advising the
Company on moving forward its research and development towards the clinic”,
said Roel Schaapveld, CEO of InteRNA Technologies. “The complementary
knowledge of the renowned clinicians and scientists in this team will play a
significant role in our R&D programs and success of the Company.”

Edwin Cuppen, scientific co-founder of InteRNA Technologies, commented:
“While fundamental research has now unequivocally demonstrated the importance
of miRNA’s in regulation and deregulation of biological processes, InteRNA
Technologies has in the past few years build up a unique position in
converting this knowledge into miRNA-based cancer treatment strategies. These
activities are now further supported by a wealth of knowledge and expertise
through this SAB, which will undoubtedly further accelerate the path towards
miRNA-based drugs.”

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to
translate its unique collection of miRNAs and miRNA discovery and validation
technologies into successful diagnostic, prognostic and therapeutic
applications. The company’s primary focus is to unravel the role of its
proprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and
has established close relationships with the research groups of its founders

Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute
(Utrecht, the Netherlands), leading scientific groups in the field of miRNA
research.

See for more information http://www.interna-technologies.com.

SOURCE InteRNA Technologies B.V.


Source: newswire



comments powered by Disqus